Vapotherm's Asthma Therapy More Effective Than Standard Oxygen Therapy In Kids

Benzinga ·  09/26 04:16

Vapotherm Inc (NASDAQ:VAPO) announced the presentation of an investigator-initiated clinical trial at the European Respiratory Society International Congress 2023, a "high flow humidified oxygen as an early intervention in children with acute severe asthma — a feasibility randomized controlled trial." The study was conducted through the Brighton and Sussex Clinical Trial Unit at University Hospitals, Sussex, England. Children who arrived at the hospital emergency department with acute, severe asthma exacerbations that did not respond to initial pharmacologic treatment were randomized to HVNI or standard nasal oxygen therapy. While 86% (19/22) of children treated with standard oxygen required escalation of therapy, only 61% (17/28)

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write first comment